医療系ベンチャー・トータルサポートオフィス：MEDISO ( Medical Innovation Support Office )

2026年8月8日（土）～2026年8月17日（月）は、休業とさせていただきます。
この期間中にお受けしたお問い合せ・ご相談の申込みについては、休業明けに対応させていただきます。
何卒ご了承のほどお願いいたします。

What is MEDISO

MEDISO provides support for business ventures, academia,
and individuals intending to put into practical use medicines,
medical devices, and regenerative medicinal products.
Click here for further details.

About the Medical Innovation Support Office

The medical innovation support office matches medical venture companies and academic institutions facing challenges in the practical application of medical products and devices for specialists* who provide detailed consultation and support for solving problems at each stage from research and development to practical use, as well as insurance coverage at clinical sites, while looking ahead to the overall comprehensive advances and dissemination into the global market.
* Specialists in each field provide support for the response to laws and regulations, marketing, business planning, fund rasing, management strategy, intellectual property management, and international development, etc.

This website is operated by Mitsubishi Research Institute, Inc., as a trustee under instructions from the Economic Affairs Division, Health Policy Bureau, and Ministry of Health, Labour and Welfare as a part of the total support for the medical ventures program sponsored by the Ministry of Health, Labour and Welfare.

Support targets

Ventures, academic institutions, and individuals aiming to put into practical use the medicines, medical devices, regenerative medicinal products, and novel drug-discovery technologies or medical materials subject to the Pharmaceuticals and Medical Devices Law.

Details of support

MEDISO provides support for the practical application of medicines, medical devices, regenerative medicinal products, and other products subject to the Pharmaceuticals and Medical Devices Law.
That support includes business planning, financing, advice on laws and regulations, and other assistance as required.

●Support method：We provide support via online meeting or e-mail.
●Support source：Support is provided in cooperation with experts in R&D, consultants in pharmaceutical affairs, and experts from related organizations including the Ministry of Health, Labour and Welfare.
●Remarks：Consultation and support services are free of charge.

Click here for inquiries

In case the link does not work, please contact us at the email address below
mediso@ml.mri.co.jp

Specialists Introduction

We will introduce registered specialists
(updated as necessary).

Tomokazu Ichikawa

Director, TM Research and Investments Pte. Ltd.

Main specialty areas

medical devices

Specialized support fields

Regulatory compliance
Business planning
Funding

Leveraged cross-functional expertise in business strategy and legal to work on strategy development, M&A, and investments in the medical device sector. Practiced law at Nagashima, Ohno and Tsunematsu, handling M&A and other corporate matters. Worked for McKinsey & Company and Hoya Corporation. Completed several acquisitions and investments in the US and Europe in the medical device business. Experienced managing a healthcare service operator in India. Currently, helping AI Medical Service, an artificial intelligence software startup for endoscope and CUC, a healthcare service provision related company. Spent more than 10 years in Singapore and familiar with business in Southeast Asian countries. Graduated from Waseda University, London Business School's Masters in Finance, and Cambridge's MBA. Attorney at law admitted in Japan.

Kazuhiro Kanmuri

Inter-Professional Inc.

Main specialty areas

medicines
regenerative medicine products

Specialized support fields

Regulatory compliance
Marketing
Business operation systems

He engaged in pharmaceutical research and development for more than 25 years. He has gained experience in Japan and in the US development organization of Daiichi Sankyo Co., Ltd., Pfizer Inc., and CRO/consulting organizations, and has been deeply involved in strategic/regulaotry planning of clinical developmentincluding overseas organizations. His specialized fields are extensive, which include company clinical trials and investigator-initiated clinical trials, organization management, strategy development, and clinical trial operation/implementation, safety and pharmacovigillance, and he is active in the academic area of regulatory science. Currently, he engages in the consulting business as an expert in clinical development/organization and human resources development through the corporation that he established by himself and specialized CRO. In addition to being the incumbent, he concurrently served as a visiting lecturer of an academia organization, and he belongs to DIA Japan, an industry association of the pharmaceutical industry, and served as the Vice Program Committee Chair of the DIA Japan annual convention in 2018.

Kazufumi Nakamura

Mitsui & Co. Global Investment, Inc.　Investment Director

Main specialty areas

medicines
regenerative medicine products

Specialized support fields

Business planning
Funding
Business operation systems
Etc

Kazufumi Nakamura is an Investment Director focused on the investment in biotech in US and China. By leveraging his experiences and networks in Pharma, Biotech and Academia, he connects companies to those experts to expand business and gain scientific insight to help the companies succeed with their important missions.
Kazufumi has over 20 years of healthcare and life sciences experience, spanning business development, investment, entrepreneurship and R&D. Prior to joining MGI, he co-founded a biotech to accelerate innovations through academic institutions in Japan. Previously, he engaged in business development and conducted scientific evaluation, and license-in and license-out of pharmaceutical products at Santen Pharmaceuticals. In addition, he was responsible for creating relationships with the leading academic institutions and innovators, gaining Santen early access to innovation. Prior to Santen, he held a number of clinical development roles at Janssen Pharmaceuticals, including the development of Alzheimer’s disease and Rheumatoid arthritis programs.

Tsutomu Hoshiba

Kievit Scientific LLC President

Main specialty areas

medicines
medical devices
regenerative medicine products

Specialized support fields

Marketing
Business planning
Etc

For over 30 years, I've established and managed Japanese life science companies in the US and Europe. In 2021, I founded Kievit Scientific in Philadelphia, utilizing my Western-acquired experience, up-to-date information, and network. I assist Japanese companies in the pharmaceutical, medical device, and chemical sectors in their international expansion, from strategic planning to product development and market entry. Harnessing my understanding of different cultures and wide-ranging scientific knowledge, I provide solutions to challenges faced by Japanese academia and startups in their global ventures, with the aim of supporting as many Japanese companies as possible to succeed overseas. Furthermore, through these endeavors, I promote the widespread adoption of innovative medical technologies, striving to realize a society where the benefits are extended to many.

Kazuhiro Terashima

CaTe inc. CEO
Fujita Health University, Department of Cardiology, Assistant Professor

Main specialty areas

medical devices

Specialized support fields

Business planning
Funding
Business operation systems
Etc

Cardiologist, Fellow of Cardiovascular Intervention and Therapeutics, Registered Cardiac Rehabilitation Instructor, Certified Occupational Health Physician and Clinical Education Instructor. He graduated from Nagoya University School of Medicine in 2011. After working at the Japanese Red Cross Aichi Medical Center, Nagoya Daiichi Hospital, Sakakibara Memorial Hospital and other institutions, he joined Fujita Health University in 2023 as Assistant Professor of Cardiology and CCU Instructor. In 2020, he founded CaTe Inc. to research and develop programmed medical devices for cardiac rehabilitation, and to conduct clinical research and company-led clinical trials of such devices. He is currently the principal investigator for basic research on the Exercise Load Optimization function, a promising technology seed. In 2023 he closed Series A funding with JAFCO etc. as lead investor. While continuing his clinical work, he serves as CEO of the company and advises and supports other clinicians in the social implementation of clinical technology seeds.

About details of specialists

Introduction of measures implemented by public institutions

We will describe the measures from public institutions for pharmaceutical companies,
medical device companies, companies manufacturing regenerative medicinal products, and venture companies.

See more about measures implemented by public institutions